Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Nov. 26, 2014, 114 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $187.00 to $173,041,515.00.

Highlighted Stocks Traded by Insiders:

Momenta Pharmaceuticals (MNTA) - FREE Research Report

Kaundinya Ganesh Venkataraman, who is Senior V.P., Research at Momenta Pharmaceuticals, sold 211 shares at $11.67 on Nov. 26, 2014. Following this transaction, the Senior V.P., Research owned 393,125 shares meaning that the stake was reduced by 0.05% with the 211-share transaction.

Shea Richard P, who is Svp, Cfo at Momenta Pharmaceuticals, sold 192 shares at $11.67 on Nov. 26, 2014. Following this transaction, the Svp, Cfo owned 177,751 shares meaning that the stake was reduced by 0.11% with the 192-share transaction.

Bishop John E, who is Senior VP, Pharmaceutical Scie at Momenta Pharmaceuticals, sold 346 shares at $11.62 on Nov. 26, 2014. Following this transaction, the Senior VP, Pharmaceutical Scie owned 108,569 shares meaning that the stake was reduced by 0.32% with the 346-share transaction.

Leicher Bruce, who is SVP & General Counsel at Momenta Pharmaceuticals, sold 192 shares at $11.67 on Nov. 26, 2014. Following this transaction, the SVP & General Counsel owned 126,998 shares meaning that the stake was reduced by 0.15% with the 192-share transaction.

Roach James M., who is Senior VP, Development and Chi at Momenta Pharmaceuticals, sold 391 shares at $11.60 on Nov. 26, 2014. Following this transaction, the Senior VP, Development and Chi owned 101,963 shares meaning that the stake was reduced by 0.38% with the 391-share transaction.

The shares most recently traded at $11.78, up $0.18, or 1.54% since the insider transaction. Historical insider transactions for Momenta Pharmaceuticals go as follows:

  • 4-Week # shares sold: 9,306
  • 12-Week # shares sold: 16,669
  • 24-Week # shares sold: 33,479

The average volume for Momenta Pharmaceuticals has been 476,300 shares per day over the past 30 days. Momenta Pharmaceuticals has a market cap of $615.9 million and is part of the health care sector and drugs industry. Shares are down 34.33% year-to-date as of the close of trading on Tuesday.

Momenta Pharmaceuticals, Inc., a biotechnology company, is engaged in the structural characterization, process engineering, and biologic systems analysis of complex molecules in the areas of complex generics, biosimilars, and novel drugs. Currently, there are 3 analysts who rate Momenta Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MNTA - FREE

TheStreet Quant Ratings

rates Momenta Pharmaceuticals as a

sell

. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full

Momenta Pharmaceuticals Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Physicians Realty (DOC) - FREE Research Report

Weiss Richard A., who is Director at Physicians Realty, bought 1,000 shares at $15.50 on Nov. 26, 2014. Following this transaction, the Director owned 15,151 shares meaning that the stake was boosted by 7.07% with the 1,000-share transaction.

The shares most recently traded at $15.53, up $0.03, or 0.19% since the insider transaction.

The average volume for Physicians Realty has been 489,500 shares per day over the past 30 days. Physicians Realty has a market cap of $731.6 million and is part of the financial sector and real estate industry. Shares are up 20.88% year-to-date as of the close of trading on Tuesday.

Physicians Realty Trust, a self-managed healthcare real estate company, focuses on the acquisition, development, ownership, and management of healthcare properties that are leased to physicians, hospitals, and healthcare delivery systems. The stock currently has a dividend yield of 5.83%. Currently, there are 7 analysts who rate Physicians Realty a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on DOC - FREE

TheStreet Quant Ratings

rates Physicians Realty as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and growth in earnings per share. However, as a counter to these strengths, we find that net income has been generally deteriorating over time. Get the full

Physicians Realty Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Derma (DSCI) - FREE Research Report

Stafford C Richard, who is Director at Derma, sold 1,775 shares at $8.26 on Nov. 26, 2014. Following this transaction, the Director owned 36,325 shares meaning that the stake was reduced by 4.66% with the 1,775-share transaction.

The shares most recently traded at $8.44, up $0.18, or 2.13% since the insider transaction. Historical insider transactions for Derma go as follows:

  • 4-Week # shares bought: 3,750
  • 4-Week # shares sold: 11,898
  • 12-Week # shares bought: 3,750
  • 12-Week # shares sold: 11,898
  • 24-Week # shares bought: 3,750
  • 24-Week # shares sold: 11,898

The average volume for Derma has been 69,200 shares per day over the past 30 days. Derma has a market cap of $210.8 million and is part of the health care sector and health services industry. Shares are down 23.29% year-to-date as of the close of trading on Tuesday.

Derma Sciences, Inc. operates as a tissue regeneration company in the wound care market. It operates in three segments: Advanced Wound Care, Traditional Wound Care, and Pharmaceutical Wound Care. Currently, there are 3 analysts who rate Derma a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DSCI - FREE

TheStreet Quant Ratings

rates Derma as a

sell

. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income and generally disappointing historical performance in the stock itself. Get the full

Derma Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null